Integral approach Sample Clauses

Integral approach. I will follow Xxxxxxxxxx’x proposal for an integral approach to explore Xxxxx’x thoughts. Xxxxxxxxxx already criticised approaching Xxxxx by quoting passages from his treatises almost at random to illustrate a point someone wishes to make. Instead of using Philo as quarry, Xxxxxxxxxx emphasised that it is important to have a grasp of the place a certain passage has within a treatise, and what place that treatise has in the whole of Xxxxx’x oeuvre, to understand what Xxxxx writes about.160 Xxxxxxxxxx further presented Xxxxx as 160 Goodenough, Introduction, p. 20. This approach is comparable to what Xxxxx describes as ‘the contextual approach’ in Runia, ‘Naming and Knowing’, pp. 69–72. Runia distinguishes roughly three approaches towards the description of Philo’s theology. These are: first, the systematic approach, where scholars ‘attempt to put together, on Xxxxx’x behalf, the systematic presentation of his doctrine of God, which he never managed (or dared) to publish’; second, the historical approach, where Xxxxx’x theology is mainly described and explained by linking and comparing his ideas and concepts to those of other authors, such as Xxxxxxxxxx and Xxxxxxxx; and third, the contextual approach, where Xxxxx is considered first and foremost an exegete, and where the starting point is taken with the analysis of someone fully integrated and interacting with his cultural surroundings, both on an intellectual and on a more popular level. Xxxxxxxxxx did not consider Xxxxx’x Jewishness as something separated from this cultural background.161 Xxxxxxxxxx therefore avoided classifying Xxxxx’x ideas as either belonging to his Jewish or his Hellenistic background and education. It took quite some time for these views to take hold in Philonic research.162 Although picking through Xxxxx’x works to illustrate a certain point still occurs occasionally, strictly differentiating between Greek or Jewish elements in Xxxxx’x thinking is hardly done anymore.163 However, one could consider attributing a special character to Xxxxx’x interaction with the Bible, setting him apart from contemporary intellectuals who explored other authoritative ancient sources, a rudimentary trace of this approach. Still, the current state of affairs in Philonic research in general is that Xxxxx is considered a Jewish thinker fully engaged and interacting with his intellectual, cultural and political environment, and that it is necessary to consider the full context of a passage to interpret wha...
AutoNDA by SimpleDocs

Related to Integral approach

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Presentation of Potential Target Businesses The Company shall cause each of the Initial Shareholders to agree that, in order to minimize potential conflicts of interest which may arise from multiple affiliations, the Initial Shareholders will present to the Company for its consideration, prior to presentation to any other person or company, any suitable opportunity to acquire an operating business, until the earlier of the consummation by the Company of a Business Combination or the liquidation of the Company, subject to any pre-existing fiduciary obligations the Initial Shareholders might have.

  • Minimum Data Necessary Shared The Provider attests that the Student Data request by the Provider from the LEA in order for the LEA to access the Provider’s products and/or services is limited to the Student Data that is adequate, relevant, and limited to what is necessary in relation to the K-12 school purposes for which it is processed.

  • CFR PART 200 Contract Provisions Explanation Required Federal contract provisions of Federal Regulations for Contracts for contracts with ESC Region 8 and TIPS Members: The following provisions are required to be in place and agreed if the procurement is funded in any part with federal funds. The ESC Region 8 and TIPS Members are the subgrantee or Subrecipient by definition. Most of the provisions are located in 2 CFR PART 200 - Appendix II to Part 200—Contract Provisions for Non-Federal Entity Contracts Under Federal Awards at 2 CFR PART 200. Others are included within 2 CFR part 200 et al. In addition to other provisions required by the Federal agency or non-Federal entity, all contracts made by the non- Federal entity under the Federal award must contain provisions covering the following, as applicable.

  • Project Implementation 2. The Borrower shall:

  • Multi-year Planning Targets Schedule A may reflect an allocation for the first Funding Year of this Agreement as well as planning targets for up to two additional years, consistent with the term of this Agreement. In such an event, the HSP acknowledges that if it is provided with planning targets, these targets:

  • Target Population The Grantee shall ensure that diversion programs and services provided under this grant are designed to serve juvenile offenders who are at risk of commitment to Department.

  • Multiple Measures of Student Learning Measures must include a combination of classroom, school and district assessments, student growth percentiles on state assessments, if state assessments are available, and student MEPA gain scores. This definition may be revised as required by regulations or agreement of the parties upon issuance of ESE guidance expected by July 2012.

Time is Money Join Law Insider Premium to draft better contracts faster.